• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Paliperidone palmitate in a child with autistic disorder.

作者信息

Kowalski Janet L, Wink Logan K, Blankenship Kelly, Habenicht Cheryl D, Erickson Craig A, Stigler Kimberly A, McDougle Christopher J

出版信息

J Child Adolesc Psychopharmacol. 2011 Oct;21(5):491-3. doi: 10.1089/cap.2011.0035.

DOI:10.1089/cap.2011.0035
PMID:22040196
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3243458/
Abstract
摘要

相似文献

1
Paliperidone palmitate in a child with autistic disorder.棕榈酸帕利哌酮用于一名患有自闭症谱系障碍的儿童。
J Child Adolesc Psychopharmacol. 2011 Oct;21(5):491-3. doi: 10.1089/cap.2011.0035.
2
Paliperidone for irritability in autistic disorder.帕利哌酮用于治疗孤独症谱系障碍的易激惹症状。
J Child Adolesc Psychopharmacol. 2010 Feb;20(1):75-8. doi: 10.1089/cap.2009.0019.
3
Paliperidone for irritability in adolescents and young adults with autistic disorder.帕利哌酮治疗孤独症谱系障碍青少年和年轻成人的易激惹。
Psychopharmacology (Berl). 2012 Sep;223(2):237-45. doi: 10.1007/s00213-012-2711-3. Epub 2012 May 3.
4
Paliperidone palmitate for schizophrenia.用于治疗精神分裂症的棕榈酸帕利哌酮
Schizophr Bull. 2012 Nov;38(6):1124-7. doi: 10.1093/schbul/sbs099. Epub 2012 Sep 10.
5
Paliperidone palmitate for refractory and clozapine-resistant schizophrenia.棕榈酸帕利哌酮用于难治性及氯氮平抵抗性精神分裂症
J Neuropsychiatry Clin Neurosci. 2015 Winter;27(1):e14-6. doi: 10.1176/appi.neuropsych.13120374. Epub 2014 Dec 12.
6
Clinical pharmacology of paliperidone palmitate a parenteral long-acting formulation for the treatment of schizophrenia.棕榈酸帕利哌酮长效注射剂治疗精神分裂症的临床药理学
Rev Recent Clin Trials. 2012 Feb;7(1):2-9. doi: 10.2174/157488712799363307.
7
Onset of efficacy and tolerability following the initiation dosing of long-acting paliperidone palmitate: post-hoc analyses of a randomized, double-blind clinical trial.长效棕榈酸帕利哌酮起始剂量后的疗效和耐受性出现时间：一项随机、双盲临床试验的事后分析。
BMC Psychiatry. 2011 May 10;11:79. doi: 10.1186/1471-244X-11-79.
8
A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia.一项针对棕榈酸帕利哌酮（长效注射用抗精神病药）的对照、基于证据的精神分裂症临床试验。
Neuropsychopharmacology. 2010 Sep;35(10):2072-82. doi: 10.1038/npp.2010.79. Epub 2010 Jun 16.
9
Comparison of rehospitalization rates and associated costs among patients with schizophrenia receiving paliperidone palmitate or oral antipsychotics.接受棕榈酸帕利哌酮或口服抗精神病药物治疗的精神分裂症患者再住院率及相关费用的比较。
Am J Health Syst Pharm. 2015 Mar 1;72(5):378-89. doi: 10.2146/ajhp140219.
10
Paliperidone palmitate for schizophrenia.用于治疗精神分裂症的棕榈酸帕利哌酮
Cochrane Database Syst Rev. 2012 Jun 13(6):CD008296. doi: 10.1002/14651858.CD008296.pub2.

引用本文的文献

1
Available Treatments for Autism Spectrum Disorder: From Old Strategies to New Options.自闭症谱系障碍的现有治疗方法：从旧策略到新选择。
Pharmaceuticals (Basel). 2025 Feb 25;18(3):324. doi: 10.3390/ph18030324.
2
Safety and Efficacy of Paliperidone Palmitate in Pediatric Patients with Autism and Intellectual Disability.棕榈酸帕利哌酮在患有自闭症和智力残疾的儿科患者中的安全性和有效性。
J Autism Dev Disord. 2024 May 13. doi: 10.1007/s10803-024-06372-9.
3
What Role for Long-Acting Injectable Antipsychotics in Managing Schizophrenia Spectrum Disorders in Children and Adolescents? A Systematic Review.长效注射抗精神病药在儿童和青少年精神分裂症谱系障碍管理中的作用？系统评价。
Paediatr Drugs. 2023 Mar;25(2):135-149. doi: 10.1007/s40272-023-00558-x. Epub 2023 Jan 20.
4
Decades of Progress in the Psychopharmacology of Autism Spectrum Disorder.自闭症谱系障碍精神药理学的几十年进展。
J Autism Dev Disord. 2021 Dec;51(12):4370-4394. doi: 10.1007/s10803-021-05237-9. Epub 2021 Sep 7.
5
Two cases of long-acting paliperidone in adolescence.青少年使用长效帕利哌酮的两例病例。
Ther Adv Psychopharmacol. 2015 Oct;5(5):304-6. doi: 10.1177/2045125315600141.
6
What's in the pipeline? Drugs in development for autism spectrum disorder.正在研发什么？针对自闭症谱系障碍的在研药物。
Neuropsychiatr Dis Treat. 2014 Feb 20;10:371-81. doi: 10.2147/NDT.S39516. eCollection 2014.
7
Pharmacologic treatments for the behavioral symptoms associated with autism spectrum disorders across the lifespan.针对自闭症谱系障碍相关行为症状的全生命周期药物治疗。
Dialogues Clin Neurosci. 2012 Sep;14(3):263-79. doi: 10.31887/DCNS.2012.14.3/cdoyle.

本文引用的文献

1
Paliperidone for irritability in autistic disorder.帕利哌酮用于治疗孤独症谱系障碍的易激惹症状。
J Child Adolesc Psychopharmacol. 2010 Feb;20(1):75-8. doi: 10.1089/cap.2009.0019.
2
Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder.阿立哌唑治疗孤独症谱系障碍儿童及青少年的易激惹症状
Pediatrics. 2009 Dec;124(6):1533-40. doi: 10.1542/peds.2008-3782.
3
A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder.一项安慰剂对照、固定剂量的阿立哌唑治疗孤独症谱系障碍相关激惹的儿童和青少年的研究。
J Am Acad Child Adolesc Psychiatry. 2009 Nov;48(11):1110-1119. doi: 10.1097/CHI.0b013e3181b76658.
4
Pharmacologic treatment of autism and related disorders.自闭症及相关障碍的药物治疗。
Pediatr Ann. 2007 Sep;36(9):575-85. doi: 10.3928/0090-4481-20070901-09.
5
Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders.利培酮治疗自闭症及其他广泛性发育障碍儿童的破坏性行为症状
Pediatrics. 2004 Nov;114(5):e634-41. doi: 10.1542/peds.2003-0264-F. Epub 2004 Oct 18.
6
Risperidone in children with autism and serious behavioral problems.利培酮用于患有自闭症及严重行为问题的儿童。
N Engl J Med. 2002 Aug 1;347(5):314-21. doi: 10.1056/NEJMoa013171.
7
A study of haloperidol in young autistic children: a within-subjects design using objective rating scales.一项针对年幼自闭症儿童的氟哌啶醇研究：采用客观评定量表的被试内设计。
Psychopharmacol Bull. 1980 Jul;16(3):63-5.
8
Haloperidol in the treatment of infantile autism: effects on learning and behavioral symptoms.氟哌啶醇治疗婴幼儿孤独症：对学习及行为症状的影响。
Am J Psychiatry. 1984 Oct;141(10):1195-202. doi: 10.1176/ajp.141.10.1195.
9
The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects.异常行为检查表：一种用于评估治疗效果的行为评定量表。
Am J Ment Defic. 1985 Mar;89(5):485-91.